Bayer will invest $2.2 billion in a new pharmaceutical manufacturing campus in New Albany, Ohio, in one of the largest recent US manufacturing commitments by the German drugmaker. The Bayer Ohio plant is expected to create about 600 permanent jobs and around 1,500 construction jobs, with the first manufacturing module due to be operational by 2031, according to the Bayer press release and the JobsOhio announcement issued on 2 October 2026.
Key Takeaways
- Bayer plans a $2.2 billion pharmaceutical manufacturing campus in the New Albany International Business Park in Ohio.
- The project is expected to create about 600 permanent high-value jobs and about 1,500 construction jobs.
- Module 1, for drug substance manufacturing, is due to be operational by 2031, and Module 2, for drug product manufacturing, by 2034.
- The site is aimed at oncology, cardiovascular and renal medicines, with a flexible, modular design and advanced digital and automation technologies.
- JobsOhio has committed up to $30 million toward an Ohio Life Science Training Center that is due to open in summer 2027.
What Is the Bayer Ohio Plant?
The Bayer Ohio plant is a planned pharmaceutical manufacturing campus that will combine two stages of making a medicine under one roof. Drug substance manufacturing produces the active ingredient, while drug product manufacturing turns it into the final form that reaches patients. Bayer says the campus will be flexible and modular, so that production can be adapted over time, and will use advanced digital and automation technologies.
The company says the therapeutic focus will be oncology, cardiovascular and renal care. Bayer did not name the specific products to be made at the site in the announcements we reviewed. Readers following the company portfolio may recall our report on the FDA expansion of Bayer Kerendia for chronic kidney disease, which covers a Bayer renal medicine.
Bayer Ohio Plant at a Glance
| Item | Detail |
|---|---|
| Company | Bayer |
| Location | New Albany International Business Park, New Albany, Ohio |
| Investment | $2.2 billion |
| Jobs | About 600 permanent; about 1,500 construction |
| Module 1 (drug substance) | Operational by 2031 |
| Module 2 (drug product) | Operational by 2034 |
| Therapeutic focus | Oncology, cardiovascular and renal care |
| Announced | 2 October 2026 |
Jobs, Timeline and Training
Bayer expects about 600 permanent jobs at the campus and about 1,500 construction jobs while it is built. The company describes the permanent roles as high-value positions, but wages and the breakdown by job type were not disclosed.
The build is phased. Module 1, for drug substance, is targeted to be operational by 2031, and Module 2, for drug product, by 2034. Before either opens, the Ohio Life Science Training Center is due to begin operating in summer 2027, so that a workforce can be trained ahead of production. According to Ohio Tech News, Ohio Life Sciences chief executive Eddie Pauline said workforce readiness was essential to the project.
Incentives and Local Support
The JobsOhio announcement says JobsOhio is committing up to $30 million for the training centre. Reports add that the city of New Albany and The New Albany Company are contributing roughly $8 million each, while the state of Ohio is contributing an unspecified amount; the sources differ slightly on how those figures are grouped, so we do not give a single total. Bayer is also expected to pursue an Ohio Job Creation Tax Credit, and details of any JobsOhio assistance are to be made public after a final agreement is signed.
Bayer joins an established life sciences cluster in New Albany that includes Amgen, American Regent, Pharmavite and Hims & Hers, which together employ more than 2,660 people, according to Ohio Tech News. Amgen is also adding 350 jobs in 2027.
What Bayer and Officials Said
Bill Anderson, Bayer chief executive, said: “The new site will be home to manufacturing expertise and a skilled workforce that will strengthen our ability to deliver innovative, high-quality medicines to patients both in the United States and abroad.” He added that the investment underscores Bayer’s commitment to the United States as a manufacturing base and innovation hub.
Sebastian Guth, global chief operating officer of Bayer Pharmaceuticals, said: “This expansion is another important step to grow our pharmaceuticals business and to meet the demand of our customers and patients in the U.S.” J.P. Nauseef, president of JobsOhio, said: “Bayer didn’t just choose a site. It chose a workforce.”
Why It Matters: US Manufacturing and Tariffs
The announcement fits a broader wave of drugmakers committing money to US production. Bloomberg framed the Bayer plan against a backdrop of US pharmaceutical tariffs. Bayer’s own release does not mention tariffs, so the link between the two is the reporter framing and not a company statement.
Bayer says the plan builds on more than $7 billion it has spent on US pharmaceutical research and development and manufacturing over the past five years. Its existing US sites include its headquarters in Whippany, New Jersey, and locations in Pittsburgh, Berkeley, Cambridge, Research Triangle Park and San Diego. Policy pressure on US drug supply and prices is also changing the industry, as seen in the Medicaid drug-pricing model that all 50 states have joined.
For India, the story is a reminder of how global supply chains are shifting. Domestic policy support for local drug and device development, such as the PRIP scheme backing 41 pharma and MedTech R&D projects, and large licensing deals such as the Novartis and Abogen mRNA deal, are part of the same competitive landscape.
What Is Not Yet Known
- Products: Bayer has not named which medicines will be made at the Ohio site.
- Capacity and site size: neither the production volumes nor the acreage were disclosed.
- Wages: average pay for the permanent jobs was not stated.
- Final incentives: JobsOhio assistance is to be made public once a final agreement is executed.
Our Assessment
In our assessment, the Bayer Ohio plant is a long-lead investment: the first module is five years away and the second eight, so it will not ease any near-term supply issues. Its significance lies in the commitment to build both drug substance and drug product capacity in the United States, which is harder to move than a contract manufacturing arrangement. The figures on jobs and timing are company targets and could change.
Frequently Asked Questions
How much is Bayer investing in Ohio?
Bayer plans to invest $2.2 billion in a new pharmaceutical manufacturing campus in New Albany, Ohio.
How many jobs will the Bayer Ohio plant create?
About 600 permanent high-value jobs and about 1,500 construction jobs are expected.
When will the plant open?
Module 1, for drug substance, is due to be operational by 2031, and Module 2, for drug product, by 2034.
What will the plant make?
Bayer says the focus is oncology, cardiovascular and renal care. Specific products were not named.
What incentives are involved?
JobsOhio has committed up to $30 million for a training centre, and local partners and the state are providing additional support. Bayer will also pursue a state job creation tax credit.
How we reported this: information comes from the Bayer press release and the JobsOhio announcement dated 2 October 2026, with additional detail from Ohio Tech News and Bloomberg. Job and timeline figures are company targets and are not independently verified. Last updated 3 October 2026. This article is for information only and is not investment advice.
[…] of Novo Denecimig Over Facility Issues Pennsylvania Measles Outbreak Nears 1,000 With 977 Cases Bayer Ohio Plant: $2.2 Billion Pharma Site in New Albany Datroway Ivonescimab Phase III Planned in First-Line TNBC Novartis Abogen Deal: $7.8 Billion […]
[…] more on pharmaceutical manufacturing and regulation, see our reports on Bayer’s $2.2 billion Ohio plant, the Maharashtra FDA action on a Cipla warehouse and India’s PRIP scheme for pharma […]